Clinical Pipeline

Clinical Trials

To learn more about our ongoing clinical trials or to find out if a study is enrolling patients in your area, please visit or email

BelumosudilPivotalKD025-213Chronic graft-versus-host disease (cGVHD) after at least 2 prior lines of systemic therapy
BelumosudilPhase 2KD025-208Chronic graft-versus-host disease (cGVHD) after 1-3 prior lines of systemic therapy
BelumosudilPhase 2KD025-209 Diffuse Cutaneous Systemic Sclerosis (SSc) – placebo-controlled
BelumosudilPhase 2KD025-215Diffuse Cutaneous Systemic Sclerosis (SSc) – open-label
BelumosudilPhase 2KD025-207Idiopathic Pulmonary Fibrosis (IPF)
KD033Phase 1KD033-101Metastatic or locally advanced solid tumors
TesevatinibPhase 2KD019-211Autosomal Dominant Polycystic Kidney (ADPKD)

At this time, Kadmon’s investigational therapies are not available on an expanded access or right-to-try basis for new patients. In the event Kadmon decides to consider expanded access or right-to-try use, the Company will evaluate and respond to each request that it receives on a case-by-case basis. For more information on our investigational therapies and ongoing clinical trials, please visit or